← Back to directory
Oncology · 肿瘤科
GI Oncology消化系统肿瘤 · Oncología Digestiva
Live now
Choose your specialist
This specialty has several focused companions, each anchored on its own world-leading clinicians and 2021–2026 evidence. Not sure which one? Start with the generalist and it will point you to the right specialist.
GeneralGI oncologyStaging & resectabilityTriage & routing
Not sure? Start hereDr. Margaret TemperoUCSF Pancreas CenterChairs the NCCN pancreatic guidelines — the staging/resectability framework
Dr. Eileen M. O'ReillyMemorial Sloan KetteringLeads precision-oncology trials — germline + somatic testing across GI cancers
Dr. Thierry ConroyInstitut de Cancérologie de LorrainePI of PRODIGE-24 — defined adjuvant mFOLFIRINOX
Gastric cancerGastric cancerHER2/Claudin18.2/MSIPerioperative & systemic
Dr. Yelena Y. JanjigianMemorial Sloan KetteringFirst author of CheckMate-649 & KEYNOTE-811 — immunotherapy in gastric cancer
Dr. Kohei ShitaraNational Cancer Center Hospital East, JapanFirst author of DESTINY-Gastric01 & SPOTLIGHT — HER2 / Claudin18.2 targeting
Dr. Salah-Eddin Al-BatranInstitute of Clinical Cancer Research, FrankfurtLed FLOT4 — the perioperative chemo standard for resectable gastric cancer
Liver cancer (HCC)Liver cancer (HCC)BCLC + Child-PughHBV surveillance
Dr. Josep M. LlovetMount Sinai / IDIBAPS BarcelonaArchitect of BCLC staging and first author of SHARP (sorafenib)
Dr. Richard S. FinnUCLAFirst author of IMbrave150 — atezolizumab+bevacizumab, the new first-line standard
Dr. Masatoshi KudoKindai University, JapanFirst author of REFLECT — lenvatinib non-inferior to sorafenib first-line
Pancreatic cancerPancreatic cancerResectability stagingPrecision oncology
Dr. Margaret TemperoUCSF Pancreas CenterChairs the NCCN pancreatic guidelines since 2000
Dr. Eileen M. O'ReillyMemorial Sloan KetteringLeads pancreatic precision-oncology — germline/somatic profiling, trial-matching
Dr. Thierry ConroyInstitut de Cancérologie de LorrainePI of PRODIGE-24 — defined adjuvant mFOLFIRINOX in resected PDAC
Peritoneal surface malignancyPeritoneal surface malignancyCRS+HIPEC candidacyConsensus-based rare-tumor decisionsImmune microenvironment framing
Dr. Paul H. SugarbakerWashington Cancer Institute (MedStar)Architect of CRS+HIPEC and the Peritoneal Cancer Index — the vocabulary this whole field speaks.
Dr. Kiran K. TuragaYale School of MedicineChairs the 2026 PSM Consortium consensus — the multi-institutional standard for rare-tumor decisions where no phase-3 RCT will ever exist.
Dr. Harriet M. KlugerYale Cancer CenterYale melanoma checkpoint immunotherapy and TIL spatial biology — reading the immune microenvironment as a place, not a single number.
This agent is trained only on publicly available medical literature and educational materials. It does not provide individualized medical advice, diagnosis, or prescription. Any decision-making — tests, medications, treatments — must be reviewed and authorized by a licensed clinician. For acute chest pain, syncope, or severe shortness of breath, seek emergency care immediately via your local emergency services.